...
首页> 外文期刊>Equine Veterinary Journal >Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.
【24h】

Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.

机译:骨髓来源的间充质干细胞的植入表明,在表浅指屈肌腱过度劳损的情况下,马的预后得到了改善。

获取原文
获取原文并翻译 | 示例
           

摘要

Reasons for performing study: Mesenchymal stem (progenitor; stromal) cell (MSC) therapy has gained popularity for the treatment of equine tendon injuries but without reports of long-term follow-up. Objectives: To evaluate the safety and reinjury rate of racehorses after intralesional MSC injection in a large study of naturally occurring superficial digital flexor tendinopathy and to compare these data with those published for other treatments. Methods: Safety was assessed clinically, ultrasonographically, scintigraphically and histologically in a cohort of treated cases: 141 client-owned treated racehorses followed-up for a minimum of 2 years after return to full work. Reinjury percentages were compared to 2 published studies of other treatments with similar selection criteria and follow-up. The number of race starts, discipline, age, number of MSCs injected and interval between injury and treatment were analysed. Results: There were no adverse effects of the treatment with no aberrant tissue on histological examination. The reinjury percentage of all racehorses with follow-up (n=113) undergoing MSC treatment was 27.4%, with the rate for flat (n=8) and National Hunt (n=105) racehorses being 50 and 25.7%, respectively. This was significantly less than published for National Hunt racehorses treated in other ways. No relationship between outcome and age, discipline, number of MSCs injected or injury to implantation interval was found. Conclusions: Whilst recognising the limitations of historical controls, this study has shown that MPC implantation is safe and appears to reduce the reinjury rate after superficial digital flexor tendinopathy, especially in National Hunt racehorses. Potential relevance: This study has provided evidence for the long-term efficacy of MSC treatment for tendinopathy in racehorses and provides support for translation to human tendon injuries.
机译:进行研究的原因:间充质干(祖细胞;基质)细胞(MSC)治疗已广泛用于治疗马腱损伤,但没有长期随访的报道。目的:在一项针对自然发生的浅表指屈肌腱病的大型研究中,评估病灶内MSC注射后赛马的安全性和再损伤率,并将这些数据与其他治疗方法进行比较。方法:在一组治疗病例中,从临床,超声,闪烁显像和组织学方面评估了安全性:141名客户拥有的治疗赛马在恢复正常工作后至少随访了2年。将再损伤百分比与选择标准和随访相似的其他治疗的2项已发表研究进行比较。分析了比赛开始的次数,纪律,年龄,注射的MSC数量以及受伤和治疗之间的间隔。结果:无异常组织的治疗对组织学检查无不良影响。所有接受MSC治疗的赛马(n = 113)的再损伤百分率是27.4%,扁平(n = 8)和国家狩猎(n = 105)赛马的再损伤率分别是50和25.7%。这大大低于以其他方式治疗的国家狩猎赛马的出版物。没有发现结果与年龄,纪律,注射的MSC数量或植入间隔的损伤之间有关系。结论:尽管认识到历史对照的局限性,但这项研究表明,MPC植入是安全的,并且似乎减少了浅指屈肌腱病后的再受伤率,尤其是在国家Hunt赛马中。潜在的相关性:这项研究为MSC治疗赛马肌腱病的长期疗效提供了证据,并为转化为人肌腱损伤提供了支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号